



Share



Tweet



Forward



In this issue: Corporate Presentations, ADR Program, Regenerative Medicine Program & Novogen Patent Update

Corporate events coming up

Dr Graham Kelly, Novogen CEO to present at the following:

- Wall Street Wonders, **17th Feb, 2015**
- Novogen Investor Briefing Forum (details below), **18th February, 2015, Yale Club, New York**
- SACHS Cancer Bio Partnering and Investor Conference - **23rd Feb, 2015, New York Academy of Science, New York**
- AusBiotech Conference Hong Kong **19,20 & 21st May, 2015, Sheraton Hotel & Towers, Hong Kong**
- Marcum Microcap Investor Conference **27 & 28th May, 2015, Grand Hyatt Hotel, New York**
- Brain Tumor Biotech Summit, **29th May, 2015, The Feinstein Institute for Medical Research, Manhasset, New York**
- BIO International Convention, **15 - 18th June, 2015, Pennsylvania Convention Centre, Philadelphia**



US Investor Briefing Forum Details

We encourage you to book in advance

When: **2.00 pm 18 February 2015**


Where: **Yale Club (Saybrook Room), 50 Vanderbilt Ave, New York.**

Booking: Please register your interest at:
prue.kelly@novogen.com.au

A video presentation of the forum will be uploaded on the Novogen website after the event

US Investor Briefing Forum


- **Yale Club (Saybrooke Room), 50 Vanderbilt Ave, New York. 2pm 18th February, 2015**
Dr Graham Kelly, Novogen Group CEO and Executive Chairman, will present an overview of the clinical and corporate strategies for the Novogen Group for 2015-2016.
Professor Gil Mor PhD MD of Yale Medical School will present a talk entitled 'Cantrixil: A Novel Therapy to Target Cancer Stem Cells to Prevent Tumor Recurrence.'
Dr Marc Symons PhD of the Feinstein Institute for Medical Research at North Shore-LIJ will present a talk entitled "Development of TRXE-009 for the Treatment of Brain Cancer."



Regenerative Medicine Program– Helping the Brain to Repair Itself

Under the direction of Dr Stephen Palmer, Novogen has an active program looking at using its super-benzopyran drug platform to develop drugs to assist the brain in repairing a wide range of injuries.

Why is it a problem worth fixing? [Read more...](#)



Protecting the drug design platforms and the lead drug candidates

A drug molecule is most valuable to a biotech company when it is “on patent”, i.e. when the company has exclusive rights to sell the drug. A patent secures an invention and grants the patent holder exclusive rights to that invention for 20 years. Therefore, a sound patent strategy is vital to ensure that maximal value is extracted from each drug a company invents. [Read more...](#)



BNY MELLON

Novogen ADR Program

Novogen securities trade on Nasdaq as Approved Depositary Receipts (ADRs). This is the form in which securities of ‘foreign’ companies are listed on US stock exchanges. Novogen is a dual-listed company whose primary listing is the Australian Securities Exchange (ASX), and so it is regarded as a ‘foreign’ company for the purposes of the SEC. [Read More...](#)



BIO & CEO Investor Conference 9th & 10th February 2015

[Click here to view presentation...](#)

Copyright © 2015 Novogen Ltd, All rights reserved.

Contact us:
pr@novogen.com

Our mailing address is:

PO Box 2333
Hornsby Westfield 1635
NSW Australia